BioWorld MedTech

July 14, 2016

Feds request additional information about Abbott's $25 billion merger with St. Jude, putting possible divestments in the cards

The U.S. Federal Trade Commission requested more information about the impending $25 billion merger of St. Jude Medical Inc. and Abbott Laboratories, meaning the earliest date at which the deal can close has been extended by 30 days. Read More

China's PMI moving forward; NHFPC names 61 projects for funding

Resilia to team up with South African distributor to market Uresta device

Clearbridge, Cambridge partner to birth, nurture Asian startup companies

Patients deserve a stronger voice in clinical trial design

Other news to note

Financings

Daily M&A

Product briefs

MDD's Orthopedics

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

BioWorld

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...